

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : FLEENOR et al.
Serial No : 10/510,585
Filed : October 8, 2004
Examiner : DAVIS, Ruth A.
Group Art Unit : 1651
Confirmation No. : 1893
Title : Agents Which Regulate, Inhibit, or Modulate The Activity and/or Expression of Connective Tissue Growth Factor (CTGF) as a Unique Means to Both Lower Intraocular Pressure and Treat Glaucomatous Retinopathies/Optic Neuropathies

**FOURTH SUPPLEMENTARY INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. 1.56, 1.97(b)(3), AND 1.98**

Mail Stop Amendment
Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. § 1.56, 1.97(b)(3), and 1.98, Applicants submit the following patents, articles and other information listed on the attached PTO Form 1449.

Applicants certify that each item of information contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application.

Because the PTO has waived the requirement under 37 CFR 1.98(a)(2) to submit copies of each cited U.S. patent and patent application publication in all U.S. national patent applications filed after June 30, 2003, none are enclosed. Only copies of cited foreign patent documents and non-patent literature are enclosed. Further, with the exception of the following two references, all other foreign patent documents and non-patent references have been submitted and are officially of record in this application and, therefore, are not enclosed. Applicants do not concede that these materials constitute prior art within the meaning of the United States patent statutes.

In re Application of : FLEENOR et al.
Serial Number : 10/510,858
Filed : October 8, 2004

Page 2

- AU2002-36641A1 (WO 03/049773A) Fibrogen 06/19/2003
- Francesca et al., IOVS, 1999; Vol. 40:2225-2234

Because each item of information contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application more than three months prior to the filing of this Statement, the Commissioner is authorized to deduct the \$180.00 fee required under 37 C.F.R. § 1.17(p) to Deposit Account No. 501051 in the name of Alcon, Inc. The Commissioner is also authorized to charge any additional fees which may be required or to credit any overpayment to Deposit Account No. 50-1051 in the name of Alcon, Inc.

Applicants request that the listed references be considered during prosecution of this application and that the references appear among the "References Cited" on any patent issuing from the application.

Respectfully submitted,

May 22, 2007
Date

/Mark E. Flanigan, Reg. No. 51681/
Mark E. Flanigan, Reg. No. 51,681
Phone: (817) 615-5080

Address for Correspondence:

Mark E. Flanigan
IP Legal, TB4-8
Alcon Research, Ltd.
6201 South Freeway
Fort Worth, Texas 76134-2099

Attorney Docket No: 2354F US